Fibroblast Pretreatment With Platelet-Rich Plasma for Disc Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for musculoskeletal disorders of the spine, particularly degenerative disc disease, fail to address the underlying cause of inflammation and disc degeneration, leading to chronic back pain and further complications.
Innovation Solution
Augmenting the therapeutic activity of fibroblasts by exposing them to platelet-rich plasma and cytokines such as FGF-alpha or FGF-beta, enhancing their anti-inflammatory, angiogenic, and regenerative properties to promote disc matrix synthesis and inhibit degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for degenerative disc disease are used, then symptoms may be temporarily managed, but the underlying inflammation and disc degeneration continue to worsen
Solution Approach 1:
The patent utilizes platelet-rich plasma, which contains natural growth factors and anti-inflammatory cytokines, to convert the body's own inflammatory response into a beneficial regenerative process. The platelets release growth factors that promote disc matrix synthesis while simultaneously reducing inflammation, thereby converting the harmful inflammatory environment into a therapeutic regenerative environment.
Solution Approach 2:
The patent introduces platelet-rich plasma as an intermediary substance that mediates between the damaged disc tissue and the immune system. This intermediary delivers concentrated growth factors and anti-inflammatory agents directly to the degenerative disc, facilitating communication and coordination between different physiological systems to achieve regeneration while controlling inflammation.
2Productivity
If fibroblasts are used for disc regeneration, then tissue repair may occur, but their therapeutic activity is insufficient to effectively counteract degradation
Solution Approach 1:
The patent changes the functional parameters of fibroblasts by exposing them to platelet-rich plasma, which alters their biochemical state. This treatment increases the fibroblasts' production of matrix components and enhances their anti-inflammatory activity, thereby changing their parameters from insufficient to effective therapeutic agents capable of counteracting matrix degradation.
Solution Approach 2:
The patent creates a composite therapeutic system combining fibroblasts with platelet-rich plasma. This composite approach integrates the matrix-producing capability of fibroblasts with the growth factor-rich environment of platelet-rich plasma, resulting in a synergistic system where fibroblasts are enhanced to simultaneously increase matrix synthesis and reduce degradation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances fibroblast efficacy in regenerating spinal discs by increasing matrix synthesis, reducing degradation, and ameliorating symptoms of disc degeneration, offering a more direct and effective treatment approach.
Implementation Method 1
contacting fibroblasts with platelet rich plasma and one or more cytokines, wherein the one or more cytokines comprise FGF-alpha or FGF-beta
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Disclosed are compositions of matter, cells, protocols and procedures useful for augmentation of one or more therapeutic activities of fibroblast cellular populations. In one embodiment fibroblasts are pretreated with growth factor-comprising composition(s), wherein the growth factor(s) may be cytokines, peptides, and/or proteins. In another embodiment fibroblasts are cultured with platelet rich plasma and/or derivatives from platelet rich plasma. In another embodiment, fibroblasts are cultured under hypoxic conditions prior to administration to an individual. The disclosure further provides means of assessment of fibroblast activity in vitro, including wound repair assay and cytokine production, for example.